Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) was up 6.3% during trading on Monday. The company traded as high as $9.79 and last traded at $9.65. 343,567 shares changed hands during mid-day trading, a decline of 72% from the average session volume of 1,225,672 shares. The stock had previously closed at $9.08.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on ZVRA shares. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Cantor Fitzgerald reduced their target price on Zevra Therapeutics from $25.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday. HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a research report on Thursday, August 20th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $23.86.
Read Our Latest Analysis on ZVRA
Zevra Therapeutics Trading Up 3.3%
The company has a market cap of $558.16 million, a price-to-earnings ratio of 7.87 and a beta of 1.01. The firm’s 50-day moving average price is $10.99 and its 200 day moving average price is $10.83.
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. The company had revenue of $37.76 million for the quarter, compared to the consensus estimate of $37.08 million. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 54.64%. Analysts forecast that Zevra Therapeutics, Inc. will post 0.88 earnings per share for the current fiscal year.
Insider Buying and Selling at Zevra Therapeutics
In other news, CEO Neil McFarlane sold 20,000 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at $4,693,781.25. This represents a 4.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.70% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new position in shares of Zevra Therapeutics during the second quarter worth approximately $28,000. Fulcrum Asset Management LLP bought a new stake in Zevra Therapeutics during the 3rd quarter valued at $31,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Zevra Therapeutics during the 3rd quarter valued at $33,000. State of Alaska Department of Revenue bought a new stake in Zevra Therapeutics during the 3rd quarter valued at $44,000. Finally, State of Wyoming acquired a new position in Zevra Therapeutics during the third quarter worth $81,000. 35.03% of the stock is owned by institutional investors and hedge funds.
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.
Featured Stories
- Five stocks we like better than Zevra Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
